| 1. | Regional Virus Research and Diagnostic Laboratory (RL-VRDL) | Dr. Lalit Dar | Department of Health Research (DHR) | 10 years (extendable) | 2019 | Continuous | ~ 5 crore |
| 2. | External Quality Assurance Scheme (EQAS) of National HIV/AIDS Reference Laboratory, AIIMS, Delhi | Dr. Bimal Kr. Das | NACO | Continuous | 2005 | Continuous | Approx. 14 lacs/annum |
| 3. | HIV integrated counseling and testing (ICTC) | Dr. Bimal Kr. Das | NACO | Continuous | 2005 | Continuous | Kits are provided by NACO and the rest is taken care of under EQAS budget |
| 4. | CD4 testing program | Dr. Bimal Kr. Das | NACO | Continuous | 2005 | Continuous | Testing kits provided by NACO, Rs. 50,000/- for Consumables |
| 5. | Evaluation of NF- κB based reactivation of latency in HIV infected individuals who are on antiretroviral therapy for more than 15 years: A Quest for Cure. | Dr. Shesh Prakash Maurya (under mentorship of Bimal Kumar Das). | Funded by DHR (HRD scheme) | 3 years | 2022 | 2025 | Rs. 50,92,497/- |
| 6. | Evaluation of role of B-1 cells in modulating the response of T cells in HIV infected patients pre and post antiretroviral therapy: cohort study. | Dr. Bimal Kumar Das | Funded by ICMR | 3 years | 2022 | 2025 | Rs. 50,40,572/- |
| 7. | Nodal coordinating center for surveillance network of antimicrobial resistance in salmonella enterica serotype Typhi and Paratyphi | Dr. Bimal Kumar Das | Funded by ICMR | 2 YEAR | 2018 | 2024 | 2,39, 22,040 |
| 8. | Detection of salmonella serovars and their associated resistance marker directly from blood specimen using paper based DNA biosensor | Dr. Bimal Kumar Das | Funded by ICMR | 2 YEAR | 2024 | 2026 | 1,35,68,808 |
| 9. | Proteomics study of Giardia intestinalis isolates to associate with different clinical spectrum and extrapolate its invasive potential | Dr. B.R Mirdha | ICMR | 3 years | Sept, 2023 | August, 2026 | 48 lakhs |
| 10. | Characterization of human antibody responses to Plasmodium vivax in India”. (Through Inspire faculty programme) | Dr. B.R Mirdha | Department of Science and Technology | 5 years | August , 2023 | 2028 | More than 5 Cr. |
| 11. | ICMRs: Advanced Mycology Diagnostic and Research Centre (AMDRC) | Prof Immaculata Xess | ICMR | 5 years | 2022 | 2027 | 250 lakhs |
| 12. | Multi-centric study on prevalence of Mycoplasma genitalium and its resistance markers in the high–risk group (MSM and FSW) attending sexually transmitted disease cclinics in North India. | Benu Dhawan | ICMR | 3 years | December 2021 | December 2024 | 28.65 Lakhs |
| 13. | Towards point of care test development for Bacterial Vaginosis, a polymicrobial infection. | Dr. Seema Sood | ICMR | 3 years | 2020 | 2023 | 51 Lakhs |
| 14. | Exploring SELEX technology for potential POCT development for Genital Chlamydia trachomatis. | Dr. Seema Sood | ICMR | 3 years | 2022 | 2025 | 50 Lakhs |
| 15. | Point-of-care test development for Bacterial Vaginosis (BV): Bench to bedside (Clinical validation of proof-of-concept). | Dr. Seema Sood | ICMR | 3 years | 2024 | 2027 | 75 Lakhs |
| 16. | Mapping hotspots of MDR-TB in Assam, Sikkim and Tripura using Genomics approaches | Dr. Urvashi B. Singh | DBT-NER | 3 years | 2018 | 2024 | ~ 4 Cr |
| 17. | Epidemiological impact and intersection of the COVID-19 and Tuberculosis Pandemics in Brazil, Russia, India and South Africa | Dr. Urvashi B. Singh | DST | 2 years | 2021 | 2023 | 1.72 Cr |
| 18. | Validation of Indigenously Developed Diagnostic kit based on Detection of Proteomic markers from Urine for Diagnosis of Pulmonary and Extra-pulmonary Tuberculosis | Dr. Urvashi B. Singh | ICMR | 3 years | 2022 | 2025 | 1.4 cr |
| 19. | Operational Feasibility and performance of indigenous phenotypic kit for detection of multidrug resistant tuberculosis and extensively drug resistant tuberculosis in field setting under the National Tuberculosis Elimination program | Dr. Urvashi B. Singh | ICMR | 3 years | 2022 | 2025 | 14 lakhs |
| 20. | Development of Surface Plasmon Resonance Array Biosensor for Rapid Molecular Drug Resistance Detection for MDR and XDR TB | Dr. Urvashi B. Singh | ICMR | 2 years | 2023 | 2025 | 40 Lakhs |
| 21. | Development of Surface Enhanced Raman Scattering (SERS) Based Biosensor for Rapid Detection of oligonucleotides in MDR and XDR-TB. | Dr. Urvashi B. Singh | AIIMS-IITD | 2 years | 2022 | 2024 | 10 Lakhs |
| 22. | A Preclinical Study to evaluate synergistic action of Rifampicin with Faropenem and Cefdinir on persister Mycobacterium tuberculosis bacilli in mouse model. | Dr. Urvashi B. Singh | AIIMS-THSTI | 2 years | 2023 | 2025 | 10 Lakhs |
| 23. | To determine the prevalence of common virulence determinants associated with Uropathogenic Escherichia coli from community-setting at different geographical regions of India using phenotypic and genotypic methods | Dr. Sarita Mohapatra | ICMR | 3 year | 2022 | 2025 | Rs553400.00 |
| 24. | Platform for discovery of novel therapeutic monoclonal antibodies against MDR and XDR Klebsiella pneumoniae | Sarita Mohapatra (Co-PI) | DBT-BIRAC | 3 years | 2023 | 2026 | Rs. 4,88,840.00 |
| 25. | Micro-nano structured urinary catheter to minimize catheter-associated urinary tract infection | Sarita Mohapatra (Co-PI) | MoE-STARS | 3 years | 2023 | 2026 | Rs 32.6 lacs |
| 26. | National Program for the Surveillance of Viral Hepatitis | Dr. Aashish Choudhary | Ministry of Health & Family Welfare (MoHFW) | 5 years (extendable) | 2020 | Continuous | ~ 1.3 crore |
| 27. | NACO Regional Reference Laboratory for HIV viral load (VL) | Dr. Aashish Choudhary | National AIDS Control Organization (NACO) | No fixed duration | 2019 | Continuous | ~ 51 lakhs |
| 28. | NACO Regional Reference Laboratory for HIV early infant diagnosis (EID) | Dr. Aashish Choudhary | National AIDS Control Organization (NACO) | No fixed duration | 2012 | Continuous | ~ 93 lakhs |
| 29. | Whole genome sequencing of the SARS-CoV-2 novel coronavirus strains at a tertiary care center in Delhi. | Dr. Aashish Choudhary | AIIMS Delhi (Intramural grant) | 2 years | 2020 | 2023 | ~ 11 lakhs |
| 30. | Molecular Epidemiology and In-Vitro Antifungal Susceptibility of Cryptic Aspergillus species from Clinical and Environment samples | Dr. Gagandeep Singh | ICMR | 3 years | 2022 | 2025 | 35 lakhs |
| 31. | Genomic profiling of invasive and hospital acquired Escherichia coli pathotypes from different clinical samples to identify the virulence and antimicrobial resistance markers | Dr. Hitender Gautam | Science & Engineering Research Board SERB (Under DST) | 2 years 6 months | Mar 2022 | Sept 2024 | 45,45,816/- |
| 32. | Site-specific biomarkers to differentiate infection from either colonization or aseptic inflammation in ICU | Dr. Hitender Gautam | ICMR | 3 years | Jan 2023 | Dec 2025 | 73,39,362/- |
| 33. | Molecular Characterization of diarrheagenic Escherichia coli among children with acute diarrhea: Association of virulence and adherence genes. | AIIMS Site PI: Dr. Hitender Gautam | Department of Health Research (DHR) | 3 years | Jan 2024 | Dec 2026 | 20,42,367/- |
| 34. | Platform for enhanced pathogen detection for meningitis and sepsis: Rapid, portable, and field-deployable diagnostics. IIRPIG-2023-0001405 | AIIMS Site PI: Dr. Hitender Gautam | ICMR | 4 years | Mar 2024 | Feb 2027 | 93,46,030/- |
| 35. | Detection of viable but non-culturable (VBNC) Gram-negative bacteria in sepsis and meningitis: Clinical significance in AMR stewardship | AIIMS Site PI: Dr. Hitender Gautam | AIIMS-THSTI Collaborative Project | 2 years | Dec 2023 | Dec 2025 | 10 Lakhs |
| 36. | Antimicrobial susceptibility patterns of pathogens isolated in bloodstream infections vis a vis antibiotic prescribing practices and genotypic clonality of Acinetobacter baumannii in various patient care units/areas | Dr. Hitender Gautam | Inter-Disciplinary AIIMS IMRG. | 1 year | Jan 2024 | Jan 2025 | 4,90,350/- |
| 37. | Clinical and epidemiological study of Lyme disease: a multi-centric taskforce study in India | Dr. Nishant Verma | ICMR | 3 | 2020 | 2023 | 3,86,71,240/- |
| 38. | Proteomics study of Giardia intestinalis isolates to associate with different clinical spectrum and extrapolate its invasive potential | Dr. Nishant Verma | ICMR | 3 | 2023 | 2026 | 48,69,222 |
| 39. | Expanded viral etiological investigation of genital ulcer disease with phenotyping and genotyping for antiviral drug resistance in herpes simplex viruses | Dr. Megha Brijwal | ICMR | 3 years | 2023 | 2026 | ~ 59 lakhs |
| 40. | Strengthening Capacity for Genomic Sequencing of Outbreak Prone Respiratory Pathogens like Influenza and Other Respiratory Viruses | Dr. Megha Brijwal | CDC & APHL, USA | 5 months | 2023 | 2023 | ~ 40 lakhs |
| 41. | Quantification of JC polyomavirus in CSF in patients with suspected progressive multifocal leukoencephalopathy (PML) by digital PCR | Dr. Megha Brijwal | AIIMS Delhi (Intramural grant) | 1 year | 2023 | 2024 | ~ 5 lakhs |
| 42. | Non-tubercular mycobacteria responsible for pulmonary disease and infections in procedures involving prosthetic devices, laparoscopy or following other interventions. | Dr. Kiran Bala | AIIMS, Intramural | 1 year | 2023 | 2024 | 4.95 Lakhs |
| 43. | Detection of Mycoplasma pneumoniae infections in acute exacerbation of Chronic Obstructive Pulmonary Disease | Dr. Tanu Sagar | AIIMS Intramural | 2 years | 2024 | 2026 | 9.8 Lakhs |
